Treg Therapy in Transplantation: How and When Will We Do It?

Niemann, Nadja; Sawitzki, Birgit

doi:10.1007/s40472-015-0066-5

Cited by 7 publications

(3 citation statements)

References 98 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell subpopulations known as "regulatory T-cells (T regs )" are experts in controlling and suppressing the immune system. Previously, in mouse hepatic allograft models, it has been demonstrated that T regs play a significant role in spontaneous graft tolerance [104,105], and there is an increase in T regs proportion in patients who are spontaneously tolerant [106]. As a result, numerous strategies for making use of their innate abilities have been thoroughly researched.…”

Section: Supporting Cellsmentioning

confidence: 99%

Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review

Ghosh,

Sanyal,

Mallick

2023

Exploration of Medicine

View full text Add to dashboard Cite

Type 1 diabetes is a chronic condition that results from the destruction of insulin-producing β-cells in the pancreas. Current treatments for type 1 diabetes, such as insulin therapy and pancreatic islet transplantation, have several limitations and, hence not quite effective in the long run. As current therapy methods fail to slow disease development, novel strategies such as the development of a bioartificial pancreas are being seriously considered. Over the last decade, research has focused on tissue engineering, which aids in the design of biological alternatives for the repair and replacement of non-functional or damaged organs. Three dimensional (3D) bioprinting technology which employs 3D printing technology to generate 3D tissue-like structures from biomaterials and cells, offers a promising solution for the treatment of type 1 diabetes by providing the ability to generate functional endocrine pancreatic tissue. Bioprinted structures are therefore an important aspect of tissue engineering because they have been found to replicate the native extracellular matrix, promoting cell survival and proliferation. In this review, recent developments in 3D bioprinting of endocrine pancreas for the treatment of type 1 diabetes particularly focussing on the choice of cells, biomaterials, growth factors, and essential considerations have been discussed in detail. Additionally, the key challenges and perspectives towards recapitulation of the pancreatic function of the pancreatic organ engineering technologies have also been discussed.

show abstract

Section: Supporting Cellsmentioning

confidence: 99%

Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review

Ghosh,

Sanyal,

Mallick

2023

Exploration of Medicine

View full text Add to dashboard Cite

show abstract

“…The motivation for the development arTregs is to reduce off-target immunosuppression; however it is possible that enhanced local bystander suppression due to activation of large numbers of arTregs could lead to an increased risk of local infection or reactivation of latent viruses present within the graft, such as BK virus in renal allografts [70] .…”

Section: Safetymentioning

confidence: 99%

Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use

Alzhrani

Bottomley

Wood

et al. 2020

Cellular Immunology

View full text Add to dashboard Cite

Highlights Tregs are a major focus of investigation in transplantation for immunosuppression minimisation. Development of alloantigen-specific Tregs has the potential to improve efficacy and safety. A number of methodologies for production exist including culture with donor alloantigen. Clinical trials of polyclonal Treg therapy are now moving into Phase II and beyond.

show abstract

“…[ 14 ] Furthermore, spontaneous allogeneic organ tolerance, a phenomenon in which transplant recipients accept the allografts without the use of immunosuppressive regimen, has been observed in liver transplant recipients with elevated Treg levels. [ 15 ] Currently, most clinical trials of Treg‐therapies utilize systemic adoptive transfer of ex vivo expanded Tregs. [ 16 ] While this method has shown promising results in clinical trials, [ 17,18 ] ex vivo expansion of Tregs requires extremely time‐consuming and costly protocols to generate appropriate numbers of cells for clinically significant results, due to the low frequency of Tregs in human peripheral blood.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of Human Natural and Induced Regulatory T‐Cells in IL‐2 and CCL1 Supplemented Alginate‐GelMA Hydrogel for 3D Bioprinting

Kim

Hope

Gantumur

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Regulatory T-cells (Tregs) are important modulators of the immune system through their intrinsic suppressive functions. Systemic adoptive transfer of ex vivo expanded Tregs has been extensively investigated for allogeneic transplantation. Due to the time-consuming and costly expansion protocols of Tregs, more targeted approaches could be beneficial. The encapsulation of human natural and induced Tregs for localized immunosuppression is described for the first time. Tregs encapsulated in alginate-gelatin methacryloyl hydrogel remain viable, phenotypically stable, functional, and confined in the structure. Supplementation of the hydrogel with the Treg-specific bioactive factors interleukin-2 and chemokine ligand 1 improves Treg viability, suppressive phenotype, and function, and attracts to the structure CCR8 + T-cells enriched with anti-inflammatory subpopulations, including Tregs, from human peripheral blood. Furthermore, these findings are applicable to 3D bioprinting. Co-axial printing of murine pancreatic islets with human natural and induced Tregs protects the islets from xenoresponse upon co-culture with human peripheral blood mononuclear cells. This establishes the co-encapsulation of Tregs by co-axial 3D bioprinting as a valid option for providing local immune protection to allogeneic cellular transplants such as pancreatic islets.

show abstract

Treg Therapy in Transplantation: How and When Will We Do It?

Cited by 7 publications

References 98 publications

Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review

Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review

Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use

Encapsulation of Human Natural and Induced Regulatory T‐Cells in IL‐2 and CCL1 Supplemented Alginate‐GelMA Hydrogel for 3D Bioprinting

Contact Info

Product

Resources

About